Adil Javed to Multiple Sclerosis
This is a "connection" page, showing publications Adil Javed has written about Multiple Sclerosis.
Connection Strength
2.062
-
Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019 Jan; 27:397-399.
Score: 0.537
-
Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Curr Opin Ophthalmol. 2009 Nov; 20(6):476-81.
Score: 0.286
-
Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther. 2006 Apr; 110(1):35-56.
Score: 0.217
-
T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and feasibility in multiple sclerosis. Neuroradiology. 2024 Oct; 66(10):1709-1719.
Score: 0.197
-
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
Score: 0.179
-
Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches. PLoS One. 2022; 17(9):e0274778.
Score: 0.175
-
COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020 Nov 15; 418:117147.
Score: 0.152
-
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
Score: 0.135
-
Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(4):e0173299.
Score: 0.120
-
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008 Feb; 7(2):173-83.
Score: 0.063